Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome

The Korean Society of Haematology AML/MDS Working Party

    Research output: Contribution to journalLetterpeer-review

    1 Citation (Scopus)
    Original languageEnglish
    Pages (from-to)e151-e155
    JournalBritish Journal of Haematology
    Volume186
    Issue number5
    DOIs
    Publication statusPublished - 2019

    Keywords

    • Hypomethylating agent
    • MDS
    • lenalidomide

    ASJC Scopus subject areas

    • Hematology

    Cite this